Genexine Inc Cash Flow Conversion Efficiency

Latest as of September 2025: -0.011x

Genexine Inc cash flow conversion efficiency. Based on the latest financial reports, Genexine Inc (095700) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.02 Million USD) by net assets (₩260.01 Billion ≈ $176.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Genexine Inc (2009–2024)

Cash flow conversion efficiency of Genexine Inc from 2009 to 2024. This chart illustrates how Genexine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Genexine Inc stock quote for real-time trading data and today's change.

Genexine Inc Cash Flow Conversion Ratio Explained

Genexine Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Genexine Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genexine Inc ranked by their cash flow conversion efficiency. Also see Genexine Inc (095700) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Redtone International Bhd KLSE:0032	-0.013x
Novotek AB ST:NTEK-B	0.124x
Powerlogics Co. Ltd KQ:047310	-0.024x
Seco/Warwick SA WAR:SWG	-0.098x
St. James's Place plc LSE:STJ	0.421x
Taiwan Allied Container Terminal TWO:5601	0.010x
Elite Express Holding Inc. Class A Common Stock NASDAQ:ETS	-0.167x
North European Oil Royalty Trust NYSE:NRT	1.270x

Annual Cash Flow Conversion Efficiency for Genexine Inc (2009–2024)

The table below shows the annual cash flow conversion efficiency of Genexine Inc from 2009 to 2024. Review cash generation quality of Genexine Inc to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩261.68 Billion ≈ $177.34 Million	₩-1.65 Billion ≈ $-1.12 Million	-0.006x	+95.09%
2023-12-31	₩296.90 Billion ≈ $201.21 Million	₩-38.05 Billion ≈ $-25.79 Million	-0.128x	+11.07%
2022-12-31	₩276.15 Billion ≈ $187.15 Million	₩-39.80 Billion ≈ $-26.97 Million	-0.144x	-485.45%
2021-12-31	₩517.74 Billion ≈ $350.87 Million	₩-12.75 Billion ≈ $-8.64 Million	-0.025x	+41.89%
2020-12-31	₩535.60 Billion ≈ $362.97 Million	₩-22.69 Billion ≈ $-15.38 Million	-0.042x	+69.74%
2019-12-31	₩296.91 Billion ≈ $201.21 Million	₩-41.57 Billion ≈ $-28.17 Million	-0.140x	-123.77%
2018-12-31	₩320.51 Billion ≈ $217.20 Million	₩-20.05 Billion ≈ $-13.59 Million	-0.063x	+72.70%
2017-12-31	₩113.91 Billion ≈ $77.19 Million	₩-26.10 Billion ≈ $-17.69 Million	-0.229x	-176.72%
2016-12-31	₩170.24 Billion ≈ $115.37 Million	₩-14.10 Billion ≈ $-9.55 Million	-0.083x	-534.09%
2015-12-31	₩125.77 Billion ≈ $85.23 Million	₩-1.64 Billion ≈ $-1.11 Million	-0.013x	-135.88%
2012-12-31	₩45.83 Billion ≈ $31.06 Million	₩1.67 Billion ≈ $1.13 Million	0.036x	+125.17%
2011-12-31	₩24.04 Billion ≈ $16.29 Million	₩-3.48 Billion ≈ $-2.36 Million	-0.145x	+17.18%
2010-12-31	₩26.43 Billion ≈ $17.91 Million	₩-4.62 Billion ≈ $-3.13 Million	-0.175x	-19184.88%
2009-12-31	₩38.50 Billion ≈ $26.09 Million	₩35.23 Million ≈ $23.87K	0.001x	--

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$65.96 Million

₩97.33 Billion KRW

Market Cap Rank

#20646 Global

#1158 in Korea

Share Price

₩2140.00

Change (1 day)

-0.93%

52-Week Range

₩2140.00 - ₩7100.00

All Time High

₩131402.78